Thomas Templeman - 02 Jun 2021 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Signature
/s/ Marella Thorell, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
02 Jun 2021
Net transactions value
+$5,000
Form type
4
Filing time
04 Jun 2021, 17:00:48 UTC
Previous filing
27 May 2021
Next filing
03 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Purchase $5,000 +250 $20.00 250 02 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Award $0 +500,338 $0.000000 500,338 20 Apr 2021 Ordinary Shares 500,338 $9.42 Direct F1, F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.
F3 This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3
F4 25% of the shares subject to such option shall vest and become exercisable on May 17, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
F5 Represented A Ordinary Shares that were redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.